Bright Minds Biosciences Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DRUG Nasdaq 2836 brightmindsbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bright Minds Biosciences Inc.

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study - Apr 28th, 2025 12:00 pm
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - Mar 4th, 2025 1:00 pm
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - Feb 24th, 2025 11:50 am
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Jan 7th, 2025 11:50 am
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - Nov 21st, 2024 2:00 pm
Bright Minds Biosciences Secures $35 Million Investment - Nov 6th, 2024 11:30 am
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - Nov 4th, 2024 7:41 pm
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data - Oct 21st, 2024 12:30 pm
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement - Oct 18th, 2024 10:50 am
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models - Oct 16th, 2024 2:45 pm
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology - Oct 16th, 2024 1:20 pm
Bright Minds is Unaware of Any Material Changes - Oct 16th, 2024 1:09 am
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events - Oct 3rd, 2024 1:00 pm
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th - Sep 19th, 2024 2:00 pm
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy - Sep 12th, 2024 12:00 pm